Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
The delta-subunit of the epithelial sodium channel (ENaC) enhances channel activity and alters proteolytic ENaC activation.
Predicted structure of MIF/CD74 and RTL1000/CD74 complexes.
Targeted ablation of oligodendrocytes induces axonal pathology independent of overt demyelination.
Rituximab: Don't Count It Out as MS Treatment
Mycoplasma pneumonia seroposivity in Iranian patients with relapsing-remitting multipl sclerosis: a randomized case-control study.
Pharmacokinetic profile of dalfampridine extended release: clinical relevance in patients with MS.
Galectin-1 for neuroprotection?
Heterogeneity at the HLA-DRB1 locus and risk for multiple sclerosis.
Effect of met-enkephalin on chromosomal aberrations in the lymphocytes of the peripheral blood of patients with multiple sclerosis.
Glatiramer acetate (copaxone) modulates platelet activation and inhibits thrombin-induced calcium influx: possible role of copaxone in targeting platelets during autoimmune neuroinflammation.
Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
Higher Relative Risk for Multiple Sclerosis in a Pediatric and Adolescent Diabetes Population: Analysis From DPV Data Base.
Retrospective US database analysis of persistence with glatiramer acetate vs. available disease-modifying therapies for multiple sclerosis: 2001-2010.
A genome screen for multiple sclerosis in Italian families.
Modulation of nitric oxide synthase by arginase and methylated arginines during the acute phase of experimental multiple sclerosis.
Expression and activation by epstein barr virus of human endogenous retroviruses-w in blood cells and astrocytes: inference for multiple sclerosis.
Daclizumab high-yield process reduced the evolution of new gadolinium-enhancing lesions to T1 black holes in patients with relapsing-remitting multiple sclerosis.
Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.
Country, Sex, EDSS Change and Therapy Choice Independently Predict Treatment Discontinuation in Multiple Sclerosis and Clinically Isolated Syndrome.
First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS.
Sodium channels contribute to microglia/macrophage activation and function in EAE and MS.
Laquinimod interferes with migratory capacity of T cells and reduces IL-17 levels, inflammatory demyelination and acute axonal damage in mice with experimental autoimmune encephalomyelitis.
Recommendations for the clinical use of motor evoked potentials in multiple sclerosis.
Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis

Pages